CDK2 and cancer: In this study, having confirmed that the gene expression of the cyclin E/CDK2 partners may be upregulated in basal-like/TNBC cells and could be targeted with small-molecule inhibitors in vitro and in vivo, we provide evidence that treatment with the CDK inhibitor SNS-032, with high affinity for CDK2 among other kinases, may upregulate PD-L1 expression by surviving cancer cells in some TNBC in vitro cellular and in vivo xenograft models.